Corrigendum to “Structure–activity study for (bis)ureidopropyl- and (bis)thioureidopropyldiamine LSD1 inhibitors with 3-5-3 and 3-6-3 carbon backbone architectures” [Bioorg. Med. Chem. 23 (2015) 1601–1612](S0968089615000735)(10.1016/j.bmc.2015.01.049);Structure-activity study for (bis)ureidopropyl- and (bis)thioureidopropyldiamine LSD1 inhibitors with 3-5-3 and 3-6-3 carbon backbone architectures

Bioorganic and Medicinal Chemistry

Volumn 23, Issue 7, 2015, Pages 1601-1612

  Nowotarski, Shannon L ^b,e   Pachaiyappan, Boobalan ^a   Holshouser, Steven L ^a   Kutz, Craig J ^a   Li, Youxuan ^a   Huang, Yi ^b,d   Sharma, Shiv K ^c   Casero, Robert A ^b   Woster, Patrick M ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Antitumor agent; Epigenetics; Histone demethylase; Lysine specific demethylase 1; Oligoamine

Indexed keywords

(BIS)THIOUREIDOPROPYLDIAMINE LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR; (BIS)UREIDOPROPYL LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR; 1,13 BIS [3 [1 (1,1 DIPHENYLMETHYL)THIOUREIDO]] 4,10 DIAZATRIDECANE DIHYDROCHLORIDE; 1,13 BIS [3 [1 (1,1 DIPHENYLMETHYL)THIOUREIDO]] 4,10 [[N (TERTBUTYL)OXYCARBONYL]] 4,10 DIAZATRIDECANE; 1,13 BIS [3 [1 (1,1 DIPHENYLMETHYL)UREIDO]] 4,10 DIAZATRIDECANE DIHYDROCHLORIDE; 1,13 BIS [3 [1 (1,1 DIPHENYLMETHYL)UREIDO]] 4,10 [[N (TERTBUTYL)OXYCARBONYL]] 4,10 DIAZATRIDECANE; 1,13 BIS [3 [1 (2,2 DIPHENYLETHYL)THIOUREIDO]] 4,10 DIAZATRIDECANE DIHYDROCHLORIDE; 1,13 BIS [3 [1 (2,2 DIPHENYLETHYL)THIOUREIDO]] 4,10 [[N (TERTBUTYL)OXYCARBONYL]] 4,10 DIAZATRIDECANE; 1,13 BIS [3 [1 (2,2 DIPHENYLETHYL)UREIDO]] 4,10 [[N (TERTBUTYL)OXYCARBONYL]] 4,10 DIAZATRIDECANE; 1,13 BIS [3 [1 (3,3 DIPHENYLPROPYL)THIOUREIDO]] 4,10 DIAZATRIDECANE DIHYDROCHLORIDE; 1,13 BIS [3 [1 (3,3 DIPHENYLPROPYL)THIOUREIDO]] 4,10 [[N (TERTBUTYL)OXYCARBONYL]] 4,10 DIAZATRIDECANE; 1,13 BIS [3 [1 (3,3 DIPHENYLPROPYL)UREIDO]] 4,10 DIAZATRIDECANE DIHYDROCHLORIDE; 1,13 BIS [3 [1 (3,3 DIPHENYLPROPYL)UREIDO]] 4,10 [[N (TERTBUTYL)OXYCARBONYL]] 4,10 DIAZATRIDECANE; 1,13 BIS [3 [1 (BENZYL)THIOUREIDO]] 4,10 DIAZATRIDECANE DIHYDROCHLORIDE; 1,13 BIS [3 [1 (BENZYL)THIOUREIDO]] 4,10 [[N (TERTBUTYL)OXYCARBONYL]] 4,10 DIAZATRIDECANE; 1,13 BIS [3 [1 (BENZYL)UREIDO]] 4,10 DIAZATRIDECANE DIHYDROCHLORIDE; 1,13 BIS [3 [1 (BENZYL)UREIDO]] 4,10 [[N (TERTBUTYL)OXYCARBONYL]] 4,10 DIAZATRIDECANE; 1,13 BIS [3 [1 (PHENYL)UREIDO]] 4,10 DIAZATRIDECANE DIHYDROCHLORIDE; 1,13 BIS [3 [1 (PHENYL)UREIDO]] 4,10 [[N (TERTBUTYL)OXYCARBONYL]] 4,10 DIAZATRIDECANE; ENZYME INHIBITOR; HISTONE H3; MESSENGER RNA; MONOAMINE OXIDASE INHIBITOR; SECRETED FRIZZLED RELATED PROTEIN 2; TRANSCRIPTION FACTOR GATA 4; TRANYLCYPROMINE; UNCLASSIFIED DRUG; VERLINDAMYCIN; CARBON; HISTONE DEMETHYLASE; KDM1A PROTEIN, HUMAN; THIOUREA;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; EPIGENETICS; GATA4 GENE; HCAD GENE; HUMAN; HUMAN CELL; IC50; MTT ASSAY; SFRP2 GENE; STRUCTURE ACTIVITY RELATION; TUMOR SUPPRESSOR GENE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; MCF-7 CELL LINE; METABOLISM; PHYSIOLOGY; PROTEIN SECONDARY STRUCTURE;

CARBON; CELL SURVIVAL; ENZYME INHIBITORS; HISTONE DEMETHYLASES; HUMANS; MCF-7 CELLS; PROTEIN STRUCTURE, SECONDARY; STRUCTURE-ACTIVITY RELATIONSHIP; THIOUREA;

EID: 84925510554     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2018.05.032     Document Type: Erratum

References (36)

1. J.C. Black, C. Van Rechem, and J.R. Whetstine Mol. Cell 48 2012 491
2. P. Marks, R.A. Rifkind, V.M. Richon, R. Breslow, T. Miller, and W.K. Kelly Nat. Rev. Cancer 1 2001 194
3. Y. Shi, and J.R. Whetstine Mol. Cell 25 2007 1
4. J.G. Herman, and S.B. Baylin N. Engl. J. Med. 349 2003 2042
5. Y. Shi, F. Lan, C. Matson, P. Mulligan, J.R. Whetstine, P.A. Cole, R.A. Casero, and Y. Shi Cell 119 2004 941
6. J.C. Culhane, and P.A. Cole Curr. Opin. Chem. Biol. 11 2007 561
7. S. Hayami, J.D. Kelly, H.S. Cho, M. Yoshimatsu, M. Unoki, T. Tsunoda, H.I. Field, D.E. Neal, H. Yamaue, B.A. Ponder, Y. Nakamura, and R. Hamamoto Int. J. Cancer 128 2011 574
8. Y. Huang, E. Greene, T.M. Stewart, A.C. Goodwin, S.B. Baylin, P.M. Woster, and R.A. Casero Proc. Natl. Acad. Sci. U.S.A. 104 2007 8023
9. T. Suzuki, and N. Miyata J. Med. Chem. 54 2011 8236
10. S.K. Sharma, S. Hazeldine, M.L. Crowley, A. Hanson, R. Beattie, S. Varghese, T.M.D. Sennanayake, A. Hirata, F. Hirata, Y. Huang, Y. Wu, N. Steinbergs, T. Murray-Stewart, I. Bytheway, J.R.A. Casero, and P.M. Woster MedChemComm 3 2012 14
11. D.M. Schmidt, and D.G. McCafferty Biochemistry 46 2007 4408
12. D.M. Gooden, D.M. Schmidt, J.A. Pollock, A.M. Kabadi, and D.G. McCafferty Bioorg. Med. Chem. Lett. 18 2008 3047
13. H. Benelkebir, C. Hodgkinson, P.J. Duriez, A.L. Hayden, R.A. Bulleid, S.J. Crabb, G. Packham, and A. Ganesan Bioorg. Med. Chem. 19 2011 3709
14. D. Ogasawara, T. Suzuki, K. Mino, R. Ueda, M.N. Khan, T. Matsubara, K. Koseki, M. Hasegawa, R. Sasaki, H. Nakagawa, T. Mizukami, and N. Miyata Bioorg. Med. Chem. 19 2011 3702
15. S. Mimasu, N. Umezawa, S. Sato, T. Higuchi, T. Umehara, and S. Yokoyama Biochemistry 49 2010 6494
16. Ortega-Munoz, A.; Castro-Palomino Laria, J.; Fyfe, M. C. T. Lysine specific demethylase-1 inhibitors and their use. PCT application WO 2011035941 A1 20110331, 2011.
17. D. Ogasawara, Y. Itoh, H. Tsumoto, T. Kakizawa, K. Mino, K. Fukuhara, H. Nakagawa, M. Hasegawa, R. Sasaki, T. Mizukami, N. Miyata, and T. Suzuki Angew. Chem., Int. Ed. 52 2013 8620
18. Y. Huang, T.M. Stewart, Y. Wu, S.B. Baylin, L.J. Marton, B. Perkins, R.J. Jones, P.M. Woster, and R.A. Casero Jr. Clin. Cancer Res. 15 2009 7217
19. T. Murray-Stewart, P.M. Woster, and R.A. Casero Jr. Amino Acids 2013
20. S. Sharma, Y. Wu, N. Steinbergs, M. Crowley, A. Hanson, R.A.J. Casero, and P. Woster J. Med. Chem. 53 2010 5197
21. B.K. Verlinden, J. Niemand, J. Snyman, S.K. Sharma, R.J. Beattie, P.M. Woster, and L.M. Birkholtz J. Med. Chem. 54 2011 6624
22. G. Jones, P. Willett, R.C. Glen, A.R. Leach, and R. Taylor J. Mol. Biol. 267 1997 727
23. O. Keller, W.E. Keller, G. van Look, and G. Wersin Org. Synth. 63 1985 160
24. F.H. Bellevue III, M. Boahbedason, R. Wu, P.M. Woster, J.R.A. Casero, D. Rattendi, S. Lane, and C.J. Bacchi Bioorg. Med. Chem. Lett. 6 1996 2765
25. X. Bi, C. Lopez, C. Bacchi, D. Rattendi, and P. Woster Bioorg. Med. Chem. Lett. 16 2006 3229
26. DePrez, P.; Lively, S. E. United States Patent Application 20080125424 2008.
27. S. Hazeldine, B. Pachaiyappan, N. Steinbergs, S. Nowotarski, A.S. Hanson, R.A. Casero Jr., and P.M. Woster J. Med. Chem. 55 2012 7378
28. N.A. Vellore, and R. Baron BMC Biophys. 6 2013 15
29. P. Bag, D. Ojha, H. Mukherjee, U.C. Halder, S. Mondal, A. Biswas, A. Sharon, L. Van Kaer, S. Chakrabarty, G. Das, D. Mitra, and D. Chattopadhyay Antiviral Res. 105 2014 126
30. Y. Wu, N. Steinbergs, T. Murray-Stewart, L.J. Marton, and R.A. Casero Biochem. J. 442 2012 693
31. S. Toyooka, K.O. Toyooka, K. Harada, K. Miyajima, P. Makarla, U.G. Sathyanarayana, J. Yin, F. Sato, N. Shivapurkar, S.J. Meltzer, and A.F. Gazdar Cancer Res. 62 2002 3382
32. Y. Shi Nat. Rev. Genet. 8 2007 829
33. L. Jin, C.L. Hanigan, Y. Wu, W. Wang, B.H. Park, P.M. Woster, and R.A. Casero Biochem. J. 449 2013 459
34. F. Forneris, C. Binda, A. Adamo, E. Battaglioli, and A. Mattevi J. Biol. Chem. 282 2007 20070
35. F.C. Bernstein, T.F. Koetzle, G.J. Williams, E.F. Meyer Jr., M.D. Brice, J.R. Rodgers, O. Kennard, T. Shimanouchi, and M. Tasumi J. Mol. Biol. 112 1977 535
36. Molecular Operating Environment (MOE), C. C. G. I., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7. 2012.